Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VNDA

Vanda Pharmaceuticals Inc

Mar 27 • 04:00PM ET

4.60

Dollar change -0.17
Percentage change -3.56	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX SAGE XENE ACAD ITCI PRTA MDGL KURA ARDX EPIX

| Held by: VTI IWM VXF IWN DFAT IBB SCHA VTWO FSMD VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.33	Insider Own	6.73%	Shs Outstand	58.31M	Perf Week	-6.50%
Market Cap	268.26M	Forward P/E	172.48	EPS next Y	0.03	Insider Trans	1.74%	Shs Float	54.39M	Perf Month	-2.34%
Income	-18.90M	PEG	-	EPS next Q	-0.57	Inst Own	75.10%	Short Float	6.55%	Perf Quarter	-1.71%
Sales	198.77M	P/S	1.35	EPS this Y	-227.27%	Inst Trans	-14.89%	Short Ratio	5.72	Perf Half Y	-7.26%
Book/sh	9.24	P/B	0.50	EPS next Y	102.47%	ROA	-2.90%	Short Interest	3.56M	Perf Year	18.86%
Cash/sh	6.42	P/C	0.72	EPS next 5Y	-	ROE	-3.49%	52W Range	3.86 - 6.75	Perf YTD	-3.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-3.46%	52W High	-31.85%	Beta	0.71
Dividend TTM	-	Quick Ratio	4.37	Sales past 5Y	-2.42%	Gross Margin	90.65%	52W Low	19.17%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	4.39	EPS Y/Y TTM	-835.29%	Oper. Margin	-20.46%	RSI (14)	42.16	Volatility	3.37% 4.35%
Employees	368	Debt/Eq	0.02	Sales Y/Y TTM	3.18%	Profit Margin	-9.51%	Recom	1.67	Target Price	12.67
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-101.92%	Payout	0.00%	Rel Volume	1.38	Prev Close	4.77
Sales Surprise	1.79%	EPS Surprise	25.02%	Sales Q/Q	17.48%	Earnings	Feb 13 AMC	Avg Volume	622.75K	Price	4.60
SMA20	-5.56%	SMA50	-1.26%	SMA200	-8.53%	Trades		Volume	860,176	Change	-3.56%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-24	Initiated	H.C. Wainwright	Buy	$18
Jul-11-24	Initiated	Cantor Fitzgerald	Overweight	$11
Feb-25-22	Downgrade	Jefferies	Buy → Hold	$24 → $12
May-12-21	Initiated	BofA Securities	Buy	$22
Jan-14-21	Downgrade	Citigroup	Buy → Neutral	$14
Oct-29-20	Upgrade	Citigroup	Neutral → Buy	$14
Jun-09-20	Downgrade	Citigroup	Buy → Neutral	$14
Mar-16-20	Downgrade	Oppenheimer	Perform → Underperform
Mar-12-20	Upgrade	Citigroup	Neutral → Buy	$14
Nov-07-19	Downgrade	Citigroup	Buy → Neutral	$19
Aug-01-19	Upgrade	Citigroup	Neutral → Buy	$19
Jul-25-19	Downgrade	Stifel	Buy → Hold	$26 → $17
Dec-11-18	Downgrade	Oppenheimer	Outperform → Perform
Dec-04-18	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Dec-04-18	Reiterated	Jefferies	Buy	$30 → $40
Nov-08-18	Resumed	Jefferies	Buy
Sep-21-18	Resumed	Oppenheimer	Outperform
May-23-18	Initiated	Citigroup	Buy	$26
Jan-19-18	Initiated	Seaport Global Securities	Buy	$20
Sep-14-17	Reiterated	Piper Jaffray	Overweight	$23 → $26

Show Previous Ratings

Feb-24-25 07:00AM	Vanda Pharmaceuticals announces the publication of an article titled 'Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S' (PR Newswire)
Feb-14-25 09:41AM	Q4 2024 Vanda Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.96%
02:20AM	Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
Feb-13-25 05:15PM	Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:18PM	Vanda: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-05-25 04:30PM	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 (PR Newswire)
Feb-04-25 06:37AM	Vanda and AnaptysBio link for generalised pustular psoriasis therapy (Pharmaceutical Technology)
Feb-03-25 07:30AM	Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist (PR Newswire)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive)
Jan-27-25 07:00AM	Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis (PR Newswire)
Jan-16-25 01:47PM	FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate (Benzinga)
Jan-08-25 04:17PM	Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review (PR Newswire)
Dec-20-24 09:13AM	Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera (PR Newswire)
Nov-12-24 04:58PM	Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences (PR Newswire)
02:21AM	Loading…
Nov-07-24 02:21AM	Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ... (GuruFocus.com)
Nov-06-24 04:12PM	Vanda: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results (PR Newswire)
Nov-01-24 02:05PM	Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst (Benzinga)
Oct-31-24 12:27PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Oct-30-24 04:30PM	Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 (PR Newswire)
Oct-15-24 08:30AM	Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals (TipRanks)
Oct-14-24 12:08PM	Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda (Bloomberg) +8.33%
10:56AM	Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. (PR Newswire)
10:37AM	Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer (Reuters)
08:19AM	Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share (Business Wire)
Sep-20-24 07:28AM	Novo sinks on obesity drug results; Sanofi reveals anticipated MS data (BioPharma Dive)
06:12AM	FDA declines approval of Vandas gastroparesis treatment (Pharmaceutical Technology)
Sep-19-24 05:20PM	Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today (Motley Fool) -6.06%
07:00AM	FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis (PR Newswire)
05:00PM	Loading…
Sep-11-24 05:00PM	Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference (PR Newswire)
Sep-04-24 05:13PM	Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference (PR Newswire)
Aug-29-24 04:30PM	Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference (PR Newswire)
Aug-01-24 08:49AM	Q2 2024 Vanda Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Jul-31-24 04:06PM	Vanda: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-26-24 09:19AM	Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024 (PR Newswire)
Jul-01-24 08:01AM	Federal Court Allows Vanda's HETLIOZ Patent Lawsuit to Proceed against Teva and Apotex (PR Newswire)
Jun-28-24 06:53AM	Cycle Pharmaceuticals offers to acquire Vanda Pharma for $466m (Pharmaceutical Technology)
Jun-21-24 07:00AM	Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs (BioPharma Dive)
Jun-19-24 08:48PM	Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders (PR Newswire)
Jun-13-24 09:00PM	Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 CAGR Of 1.98% (GlobeNewswire) +9.80%
10:02AM	Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak (PR Newswire)
Jun-07-24 06:02AM	Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains? (Zacks)
Jun-06-24 09:24AM	Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd. (PR Newswire) +24.16%
08:00AM	Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share (Business Wire)
07:38AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-30-24 05:20PM	Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference (PR Newswire)
04:48PM	Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY (PR Newswire)
May-29-24 02:17PM	Vanda Pharmaceuticals Announces Presentations at SLEEP 2024 (PR Newswire)
May-24-24 04:46PM	Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders (PR Newswire) +6.52%
May-16-24 11:24AM	Vanda (VNDA) Rises on Positive Data From Motion Sickness Study (Zacks)
06:22AM	Vanda Pharmaceuticals reports positive data from motion sickness trial (Clinical Trials Arena)
May-15-24 01:04PM	Vanda Pharmaceuticals Says Second Phase 3 Study of Tradipitant in Motion Sickness Yields 'Positive' Results (MT Newswires)
08:45AM	Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness (PR Newswire)
May-10-24 03:24PM	Vanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue Estimates (GuruFocus.com)
May-09-24 12:37PM	Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2024 Earnings Call Transcript (Insider Monkey) -6.53%
06:43AM	Q1 2024 Vanda Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:38AM	Vanda Pharmaceuticals Inc (VNDA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-08-24 08:58PM	VNDA Stock Earnings: Vanda Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:10PM	Vanda: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results (PR Newswire)
May-07-24 11:33AM	Vanda Pharmaceuticals Shares Rise After Future Pak Adds $260 Million Potential Payments to Cash Offer (MT Newswires) +13.22%
11:16AM	Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak (PR Newswire)
09:22AM	UPDATE 3-Future Pak sweetens take-private offer for Vanda Pharmaceuticals (Reuters)
09:10AM	Future Pak increases buyout offer for Vanda Pharmaceuticals (Reuters)
09:00AM	Future Pak Increases Bid for Vanda Pharmaceuticals to Include CVRs in Addition to $7.25 to $7.75 Per Share in Cash (Business Wire)
Apr-30-24 04:30PM	Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024 (PR Newswire)
Apr-25-24 10:45AM	UPDATE 1-Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer (Reuters)
09:00AM	Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer (Reuters)
08:05AM	Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals (GlobeNewswire)
Apr-24-24 06:00PM	Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know (Zacks)
01:58PM	Vanda (VNDA) to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-22-24 07:13PM	Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ ANDA Litigation (PR Newswire) -6.07%
04:11PM	Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court (MT Newswires)
11:37AM	UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents (Reuters)
10:09AM	U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents (Reuters)
Apr-19-24 01:06PM	Butler Hall Capital urges Vanda to engage in sales discussions (Reuters)
Apr-18-24 09:44AM	Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up (Zacks) -5.15%
09:00AM	Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know (Zacks)
Apr-17-24 02:29PM	Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share (Benzinga) +29.38%
11:53AM	Why Vanda Pharmaceuticals Stock Is Skyrocketing Today (Motley Fool)
10:21AM	Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan (PR Newswire)
09:11AM	Vanda Pharmaceuticals rejects takeover proposal from Future Pak (Reuters)
09:02AM	Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak (PR Newswire)
08:32AM	Why Is Vanda Pharmaceuticals (VNDA) Stock Up 34% Today? (InvestorPlace)
06:30AM	Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash (Business Wire)
Apr-15-24 06:00PM	Vanda Pharmaceuticals (VNDA) Declines More Than Market: Some Information for Investors (Zacks)
Apr-10-24 06:15PM	Vanda Pharmaceuticals (VNDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
Apr-04-24 07:52AM	Vanda (VNDA) Soars 29.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-03-24 12:02PM	Vanda (VNDA) Up on FDA Nod for Fanapt in Bipolar I Disorder (Zacks) +29.16%
10:48AM	Why Is Vanda Pharmaceuticals Stock Trading Higher Today? (Benzinga)
10:00AM	Why Is Vanda Pharmaceuticals (VNDA) Stock Up 33% Today? (InvestorPlace)
Apr-02-24 06:10PM	Vanda Pharmaceuticals' Fanapt (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder (PR Newswire) -5.10%
Mar-07-24 10:47AM	Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia (Zacks)
Mar-06-24 11:55PM	Chairman of Vanda Pharmaceuticals Inc (VNDA) Sells Shares (GuruFocus.com) -5.56%
07:00AM	Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ in the Treatment of Insomnia (PR Newswire)
Feb-14-24 04:22AM	Jim Simons Adds Vanda Pharmaceuticals to Portfolio in Recent Trade (GuruFocus.com)
Feb-12-24 12:20PM	Earnings Estimates Moving Higher for Vanda (VNDA): Time to Buy? (Zacks)
Feb-08-24 09:38AM	Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2023 Earnings Call Transcript (Insider Monkey) +11.81%

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Polymeropoulos Mihael Hristos	President and CEO	Mar 06 '25	Buy	5.01	10,000	50,150	2,295,731	Mar 06 05:53 PM
Polymeropoulos Mihael Hristos	President and CEO	Mar 05 '25	Buy	5.02	10,000	50,200	2,285,731	Mar 05 05:19 PM
Polymeropoulos Mihael Hristos	President and CEO	Mar 03 '25	Buy	4.71	10,000	47,050	2,275,731	Mar 04 04:45 PM
Polymeropoulos Mihael Hristos	President and CEO	Feb 28 '25	Buy	4.76	10,000	47,600	2,361,730	Feb 28 05:30 PM
Polymeropoulos Mihael Hristos	President and CEO	Feb 27 '25	Buy	4.76	10,000	47,600	2,351,730	Feb 27 04:13 PM
Polymeropoulos Mihael Hristos	President and CEO	Feb 26 '25	Buy	4.76	10,000	47,650	2,341,730	Feb 26 04:46 PM
Polymeropoulos Mihael Hristos	President and CEO	Feb 25 '25	Buy	4.46	10,000	44,640	2,331,730	Feb 25 07:38 PM
Moran Kevin Patrick	SVP, CFO & Treasurer	Feb 21 '25	Buy	4.39	2,000	8,779	355,763	Feb 24 07:04 PM
Mitchell Stephen Ray	Director	Nov 14 '24	Sale	5.17	5,000	25,863	44,857	Nov 18 05:45 PM
Mitchell Stephen Ray	Director	Nov 14 '24	Proposed Sale	5.40	5,000	27,000		Nov 14 04:10 PM
Moran Kevin Patrick	SVP, CFO & Treasurer	Jul 29 '24	Sale	5.92	2,251	13,327	228,763	Jul 29 05:24 PM
Moran Kevin Patrick	Officer	Jul 29 '24	Proposed Sale	5.92	2,251	13,327		Jul 29 05:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VNDA

Vanda Pharmaceuticals Inc

Upgrade your FINVIZ experience